Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in HCC Patients After Lenvatinib Progression
NCT04080154Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Progression-Free Survival up to 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04080154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080154.